[go: up one dir, main page]

PT2533050E - Opções de tratamento para a doença de fabry - Google Patents

Opções de tratamento para a doença de fabry Download PDF

Info

Publication number
PT2533050E
PT2533050E PT121684518T PT12168451T PT2533050E PT 2533050 E PT2533050 E PT 2533050E PT 121684518 T PT121684518 T PT 121684518T PT 12168451 T PT12168451 T PT 12168451T PT 2533050 E PT2533050 E PT 2533050E
Authority
PT
Portugal
Prior art keywords
treatment options
fabry disease
fabry
disease
options
Prior art date
Application number
PT121684518T
Other languages
English (en)
Inventor
David Lockhart
Jeff Castelli
Original Assignee
Amicus Therapeutics Inc
Nat Inst Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38723987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2533050(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc, Nat Inst Health filed Critical Amicus Therapeutics Inc
Publication of PT2533050E publication Critical patent/PT2533050E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G01N2333/94—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Ecology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT121684518T 2006-05-16 2007-05-16 Opções de tratamento para a doença de fabry PT2533050E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80108906P 2006-05-16 2006-05-16
US85363106P 2006-10-23 2006-10-23

Publications (1)

Publication Number Publication Date
PT2533050E true PT2533050E (pt) 2014-05-26

Family

ID=38723987

Family Applications (1)

Application Number Title Priority Date Filing Date
PT121684518T PT2533050E (pt) 2006-05-16 2007-05-16 Opções de tratamento para a doença de fabry

Country Status (18)

Country Link
US (9) US7851143B2 (pt)
EP (5) EP2955520B1 (pt)
JP (6) JP2009537149A (pt)
AU (1) AU2007253900A1 (pt)
CA (1) CA2652553C (pt)
CY (3) CY1115180T1 (pt)
DK (2) DK2533050T6 (pt)
ES (3) ES2464527T7 (pt)
HK (3) HK1178975A1 (pt)
HU (2) HUE027569T2 (pt)
LT (1) LTC2787345I2 (pt)
LU (1) LU93312I2 (pt)
MX (2) MX2008014679A (pt)
NL (1) NL300843I2 (pt)
PL (2) PL2533050T6 (pt)
PT (1) PT2533050E (pt)
SI (2) SI2787345T1 (pt)
WO (1) WO2007137072A2 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2533050E (pt) 2006-05-16 2014-05-26 Amicus Therapeutics Inc Opções de tratamento para a doença de fabry
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
MX2009011473A (es) * 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
DK3470077T3 (da) * 2008-02-12 2020-11-30 Amicus Therapeutics Inc Fremgangsmåde til forudsigelse af respons på behandling af sygdomme med farmakologiske chaperoner
MX2010009875A (es) * 2008-03-12 2010-11-26 Amicus Therapeutics Inc Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de pompe.
ES2568610T3 (es) * 2009-11-17 2016-05-03 Baylor Research Institute Triaosilceramida (Gb3) urinaria como un marcador de cardiopatías
CA2791994A1 (en) * 2010-03-05 2011-09-09 Baylor Research Institute Involvement of androgen/androgen receptor pathway in fabry disease
MX2013010446A (es) * 2011-03-11 2014-03-27 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de la enfermedad de fabry.
PT2707101T (pt) 2011-05-12 2019-05-30 Proteostasis Therapeutics Inc Reguladores da proteostase
CA2860085A1 (en) * 2011-12-22 2013-06-27 Centogene Ip Gmbh Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
AU2013202368B2 (en) 2012-01-25 2016-06-16 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
WO2014127038A1 (en) * 2013-02-12 2014-08-21 Baylor Research Institute Methods and compositions related to calcium homeostasis and fabry disease
CN105828811B (zh) * 2013-12-23 2022-04-08 Bcn肽类股份有限公司 用于在溶酶体贮积症或糖原贮积病的治疗中使用的作为胞吐作用活化化合物的比卡鲁胺类似物或(s)-比卡鲁胺
US9675627B2 (en) * 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
JP6770945B2 (ja) * 2014-07-25 2020-10-21 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヒト４−リン酸アダプタータンパク質２糖脂質移行タンパク質様ドメインの結晶構造
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
EP4324521A3 (en) * 2016-07-19 2024-04-24 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naive and ert-experienced patients
US12020820B1 (en) 2017-03-03 2024-06-25 Cerner Innovation, Inc. Predicting sphingolipidoses (fabry's disease) and decision support
US11335461B1 (en) 2017-03-06 2022-05-17 Cerner Innovation, Inc. Predicting glycogen storage diseases (Pompe disease) and decision support
KR20240017112A (ko) 2017-05-30 2024-02-06 아미쿠스 세라퓨틱스, 인코포레이티드 신장 손상을 갖는 파브리 환자를 치료하는 방법
ES2970419T3 (es) * 2017-05-30 2024-05-28 Amicus Therapeutics Inc Migalastat para el tratamiento de pacientes de Fabry que tienen disfunción renal
US11923048B1 (en) 2017-10-03 2024-03-05 Cerner Innovation, Inc. Determining mucopolysaccharidoses and decision support tool
JP7555818B2 (ja) 2018-02-06 2024-09-25 アミカス セラピューティックス インコーポレイテッド 妊娠患者におけるファブリー病の治療のためのミガラスタットの使用
PL3749308T3 (pl) * 2018-02-06 2024-03-25 Amicus Therapeutics, Inc. Leczenie pacjentów z klasyczną chorobą fabry’ego migalastatem
CN112585130A (zh) 2018-06-27 2021-03-30 蛋白质平衡治疗股份有限公司 蛋白酶体活性增强化合物
BR112020026580A2 (pt) 2018-06-27 2021-03-23 Proteostasis Therapeutics, Inc. (Fem) Compostos, composição farmacêutica e métodos para tratar um paciente
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
US11833164B2 (en) 2019-08-07 2023-12-05 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
US11191827B1 (en) * 2020-12-09 2021-12-07 Tevogen Bio Inc. COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463109A4 (en) * 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
WO1992000277A1 (fr) * 1990-06-29 1992-01-09 Nippon Shinyaku Co., Ltd. Derive de piperidine
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
AU734905B2 (en) 1996-04-10 2001-06-28 Regents Of The University Of California, The Correction of genetic defects using chemical chaperones
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US7842470B2 (en) 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
MX344587B (es) 2003-01-31 2016-12-20 Mount Sinai School Of Medicine Of New York Univ Metodo para incrementar la estabilidad in vitro e in vivo de enzimas asociadas al transtorno lisosomal.
US7446098B2 (en) * 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
EP1633356A1 (en) * 2003-05-22 2006-03-15 The Hospital for Sick Children Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
ES2402182T3 (es) 2003-11-12 2013-04-29 Amicus Therapeutics Inc. Derivados de hidroxipiperidina para tratar la enfermedad de Gaucher
KR20080025373A (ko) 2005-05-17 2008-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 1-데옥시노지리마이신 및 유도체를 이용한 폼페병의 치료방법
JP2009509913A (ja) 2005-06-08 2009-03-12 アミカス セラピューティックス インコーポレイテッド リソソーム酵素をコードする遺伝子の変異に関連するｃｎｓ障害の治療
WO2008045015A1 (en) 2005-06-08 2008-04-17 Amicus Therapeutics, Inc. Imino and amino sugar purification
US20100004156A1 (en) 2005-07-27 2010-01-07 Shalesh Kaushal Small Compounds That Correct Protein Misfolding and Uses Thereof
EP1982189A4 (en) 2006-01-27 2010-09-08 Univ Leland Stanford Junior COMPOSITIONS AND METHODS FOR SCREENING WITH HIGH PASSAGE OF PHARMACOLOGICAL CHAPTERS
PT2533050E (pt) 2006-05-16 2014-05-26 Amicus Therapeutics Inc Opções de tratamento para a doença de fabry
WO2008034628A1 (en) 2006-09-22 2008-03-27 Krka, Tovarna Zdravil, D.D., Novo Mesto Aripiprazole hemifumarate and process for its preparation
JP2010523578A (ja) 2007-03-30 2010-07-15 アミカス セラピューティックス インコーポレイテッド 薬理シャペロンを用いるファブリー病の治療方法
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
MX2009011473A (es) 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
DK3470077T3 (da) 2008-02-12 2020-11-30 Amicus Therapeutics Inc Fremgangsmåde til forudsigelse af respons på behandling af sygdomme med farmakologiske chaperoner
WO2010048532A1 (en) 2008-10-24 2010-04-29 Amicus Therapeutics, Inc. Multiple compartment dosing model
AU2010254092B2 (en) 2009-05-26 2015-11-12 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
US9206457B2 (en) 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
ES2568610T3 (es) 2009-11-17 2016-05-03 Baylor Research Institute Triaosilceramida (Gb3) urinaria como un marcador de cardiopatías
MX2013010446A (es) 2011-03-11 2014-03-27 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de la enfermedad de fabry.
WO2014014938A1 (en) 2012-07-17 2014-01-23 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
CN109069494A (zh) 2016-03-22 2018-12-21 阿米库斯治疗学公司 治疗在gla基因中具有g9331a突变的患者的法布里病的方法
EP4324521A3 (en) 2016-07-19 2024-04-24 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naive and ert-experienced patients
US11357834B2 (en) 2017-01-10 2022-06-14 Amicus Therapeutics, Inc. Recombinant α-galactosidase A for treatment of Fabry disease
KR20240017112A (ko) 2017-05-30 2024-02-06 아미쿠스 세라퓨틱스, 인코포레이티드 신장 손상을 갖는 파브리 환자를 치료하는 방법
EA202090242A1 (ru) 2017-07-19 2020-05-26 Амикус Терапьютикс, Инк. Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
LT3675853T (lt) 2017-08-28 2022-12-12 Amicus Therapeutics, Inc. Fabri liga sergančių pacientų širdies funkcijos stiprinimo ir (arba) stabilizavimo būdai
JP7555818B2 (ja) 2018-02-06 2024-09-25 アミカス セラピューティックス インコーポレイテッド 妊娠患者におけるファブリー病の治療のためのミガラスタットの使用
PL3749308T3 (pl) 2018-02-06 2024-03-25 Amicus Therapeutics, Inc. Leczenie pacjentów z klasyczną chorobą fabry’ego migalastatem
EA202190569A1 (ru) 2018-08-20 2021-06-01 Амикус Терапьютикс, Инк. Способы лечения болезни фабри у пациентов, имеющих мутацию в гене gla
EA202290024A1 (ru) 2019-06-11 2022-03-14 Амикус Терапьютикс, Инк. Способы лечения болезни фабри у пациентов с почечной недостаточностью
US11833164B2 (en) 2019-08-07 2023-12-05 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene

Also Published As

Publication number Publication date
US20180250279A1 (en) 2018-09-06
WO2007137072A3 (en) 2008-10-16
JP2013100307A (ja) 2013-05-23
SI2787345T1 (sl) 2016-08-31
EP2024745A4 (en) 2010-03-17
JP6026268B2 (ja) 2016-11-16
ES2464527T9 (es) 2015-07-24
US9987263B2 (en) 2018-06-05
US20180325881A1 (en) 2018-11-15
NL300843I2 (pt) 2016-12-21
DK2533050T3 (da) 2014-06-02
PL2533050T6 (pl) 2016-05-31
JP7175297B2 (ja) 2022-11-18
EP2787345B8 (en) 2016-04-13
EP2955520B1 (en) 2018-10-31
EP3457135A1 (en) 2019-03-20
AU2007253900A1 (en) 2007-11-29
US20080056994A1 (en) 2008-03-06
US7851143B2 (en) 2010-12-14
EP2787345A1 (en) 2014-10-08
HK1129458A1 (en) 2009-11-27
WO2007137072A2 (en) 2007-11-29
DK2533050T6 (da) 2015-09-21
JP2018138564A (ja) 2018-09-06
EP2533050A1 (en) 2012-12-12
JP2023027053A (ja) 2023-03-01
HK1218955A1 (zh) 2017-03-17
CY2016040I1 (el) 2017-06-28
US20150238474A1 (en) 2015-08-27
DK2787345T3 (en) 2016-05-30
EP2787345B1 (en) 2016-02-24
US20110104727A1 (en) 2011-05-05
HUE027569T2 (en) 2016-10-28
JP2016006088A (ja) 2016-01-14
ES2464527T7 (es) 2015-09-14
HK1178975A1 (en) 2013-09-19
EP2024745B1 (en) 2015-07-08
US9480682B2 (en) 2016-11-01
HUS1600048I1 (hu) 2017-01-30
CA2652553C (en) 2020-08-18
ES2573498T3 (es) 2016-06-08
JP2009537149A (ja) 2009-10-29
US20170042868A1 (en) 2017-02-16
EP2533050B3 (en) 2015-06-24
US11241422B2 (en) 2022-02-08
LU93312I2 (fr) 2017-01-26
EP2955520A1 (en) 2015-12-16
ES2464527T3 (es) 2014-06-03
JP6800176B2 (ja) 2020-12-16
CY2016040I2 (el) 2017-06-28
US10406143B2 (en) 2019-09-10
CY1117656T1 (el) 2017-05-17
EP2024745A2 (en) 2009-02-18
PL2787345T3 (pl) 2016-08-31
US9000011B2 (en) 2015-04-07
CY1115180T1 (el) 2016-12-14
US20220160690A1 (en) 2022-05-26
ES2709445T3 (es) 2019-04-16
US20190388409A1 (en) 2019-12-26
CA2652553A1 (en) 2007-11-29
LTPA2016033I1 (lt) 2016-12-12
LTC2787345I2 (lt) 2017-10-10
PL2533050T3 (pl) 2014-08-29
EP3457135B1 (en) 2024-12-04
US20120220632A1 (en) 2012-08-30
EP2533050B1 (en) 2014-03-12
JP2020196717A (ja) 2020-12-10
MX2008014679A (es) 2009-04-14
MX351004B (es) 2017-09-26
SI2533050T1 (sl) 2014-07-31
US10383864B2 (en) 2019-08-20

Similar Documents

Publication Publication Date Title
HK1218955A1 (zh) 法布瑞氏症的治療選項
GB0610680D0 (en) Therapeutic compounds
IL193678A0 (en) Therapeutic compounds
GB0624874D0 (en) Treatment
GB0603041D0 (en) Therapeutic compounds
HK1203925A1 (en) Therapeutic compounds
GB0600692D0 (en) Well treatment
GB0606663D0 (en) Therapeutic compounds
GB0711342D0 (en) Well treatment
GB0615809D0 (en) Therapeutic compounds
EP1889618A4 (en) COMBINED MEDICATION FOR THE TREATMENT OF DIABETES
GB0612971D0 (en) Therapeutic compounds
GB0625349D0 (en) Therapeutic compounds
GB0607952D0 (en) Novel treatment
GB0625345D0 (en) Therapeutic compounds
GB0701456D0 (en) Treatment for respiratory disease
GB0605573D0 (en) Therapeutic Compounds
GB0603455D0 (en) Therapeutic compounds
GB0604460D0 (en) Treatment
GB0608269D0 (en) Therapeutic compounds
GB2439923B (en) Therapeutic compounds
GB0604130D0 (en) Treatment for skin disease
GB0605781D0 (en) Treatment
GB0610431D0 (en) Treatment
GB0600817D0 (en) Medical treatment